Preparation of Cell Cultures and Vaccinia Virus Stocks
10.1002/cpps.34 · doi-reference
Vaccination induces HIV broadly neutralizing antibody precursors in humans
10.1126/science.add6502 · doi-reference
Two noncompeting human neutralizing antibodies targeting MPXV B6 show protective effects against orthopoxvirus infections
10.1038/s41467-024-48312-2 · doi-reference
Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates
10.1016/j.cell.2024.08.043 · doi-reference
Multi-valent mRNA vaccines against monkeypox enveloped or mature viron surface antigens demonstrate robust immune response and neutralizing activity
10.1007/s11427-023-2378-x · doi-reference
Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge
10.1128/jvi.79.21.13454-13462.2005 · doi-reference
Immunogenicity and protection efficacy of monovalent and polyvalent poxvirus vaccines that include the D8 antigen
10.1016/j.virol.2006.07.017 · doi-reference
Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement
10.1128/jvi.01797-08 · doi-reference
A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies
10.1006/viro.1995.1378 · doi-reference
Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge
10.1128/jvi.01854-07 · doi-reference
An mpox virus mRNA-lipid nanoparticle vaccine confers protection against lethal orthopoxviral challenge
10.1126/scitranslmed.adg3540 · doi-reference
Human antibody responses to circulating monkeypox virus emphasise the need for the first mpox-specific vaccine
10.1016/s2666-5247(23)00365-8 · doi-reference
Polyvalent mpox mRNA vaccines elicit robust immune responses and confer potent protection against vaccinia virus
10.1016/j.celrep.2024.114269 · doi-reference
Monkeypox virus-infected individuals mount comparable humoral immune responses as smallpox-vaccinated individuals
10.1038/s41467-023-41587-x · doi-reference
A multivalent mRNA monkeypox virus vaccine (BNT166) protects mice and macaques from orthopoxvirus disease
10.1016/j.cell.2024.01.017 · doi-reference
Dendritic cell subsets in T cell programming: location dictates function
10.1038/s41577-018-0088-1 · doi-reference
Programming the magnitude and persistence of antibody responses with innate immunity
10.1038/nature09737 · doi-reference
Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus
10.1016/j.cell.2019.01.046 · doi-reference
Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns
10.1038/nri2868 · doi-reference
Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens
10.1016/j.immuni.2017.11.023 · doi-reference
Protein Nanoparticle-Mediated Delivery of Recombinant Influenza Hemagglutinin Enhances Immunogenicity and Breadth of the Antibody Response
10.1021/acsinfecdis.2c00362 · doi-reference
Rapid and highly potent humoral responses to mpox nanovaccine candidates adjuvanted by thermostable scaffolds
10.1016/j.vaccine.2024.02.027 · doi-reference
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
10.1126/science.abf6840 · doi-reference
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein
10.1016/j.hlife.2023.09.003 · doi-reference
Viral targets for vaccines against COVID-19
10.1038/s41577-020-00480-0 · doi-reference
Global public health crisis response: A roundtable discussion with Professor George Fu Gao, Professor Jules A Hoffmann, Professor Chris Walzer and Professor Jiahai Lu
10.1016/j.hlife.2023.10.001 · doi-reference
Time is now: Preparing for the next pandemic
10.1016/j.hlife.2024.12.008 · doi-reference
Rational design of a “two-in-one” immunogen DAM drives potent immune response against mpox virus
10.1038/s41590-023-01715-7 · doi-reference
Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens
10.1038/s41422-023-00792-5 · doi-reference
Cross-reactive immune responses to monkeypox virus induced by MVA vaccination in mice
10.1186/s12985-023-02085-0 · doi-reference
Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin
10.1073/pnas.1115485109 · doi-reference
Mosaic RBD nanoparticle elicits immunodominant antibody responses across sarbecoviruses
10.1016/j.celrep.2024.114235 · doi-reference
Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models
10.1126/science.abq0839 · doi-reference
